Assembly Biosciences to Present Data at The International

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials

—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties—

—Planning to Start Phase 1 Trials in 2H16 While Also Advancing Additional CpAM Compounds—

BARCELONA, Spain and NEW YORK, April 13, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB ), a public biotechnology company advancing a novel class of oral biologic therapeutics designed to treat diseases of the gut microbiome and an innovative discovery platform of best-in-class oral small molecule therapeutics for the treatment of hepatitis B virus (HBV) infection, today announced that it will present preclinical data on its unique series of HBV Core Protein Allosteric Modifiers (CpAMs) at The International Liver Congress TM 2016 in Barcelona, Spain on April 15, 2016.

The presentation describes a new series of CpAMs that prevents the formation of new cccDNA and inhibits core protein functions. Within the series, different CpAM molecules demonstrated distinct and potent antiviral and binding profiles. This is consistent with the known properties of CpAMs, which can allosterically modify the activity of core protein. In cell-based studies, CpAMs were selective and specific to HBV and were not cytotoxic. In animal studies, a prototype compound in the series demonstrated attractive pharmacokinetic properties consistent with once-daily oral administration in humans, including a long half-life and good oral bioavailability.

CpAMs interrupt viral replication by a different mechanism than current HBV treatments and can be used in combination with existing therapies. In a combination study with entecavir, a nucleoside polymerase inhibitor which is a current standard of care therapy for HBV, CpAMs exhibited the potential to achieve additive, and possibly synergistic effects, with no evidence of drug antagonism. The researchers concluded that the overall study data support the ongoing advancement of candidate compounds from this series of CpAMs into the IND-enabling animal toxicology studies that are a prerequisite for human clinical trials.

“These preclinical profiling studies confirm that our CpAMs have unique properties compared to current therapies,” said Richard Colonno, PhD, Chief Scientific Officer of Assembly Biosciences. “The studies with our first generation CpAMs demonstrate their ability to effectively inhibit the formation of new cccDNA, a key distinction from the activity of nucleoside and nucleotide analogs used to treat HBV today. We are on track to move one of our compounds from this series into human clinical trials later this year, as we also continue to pursue additional candidates from this and other chemical series. Assembly expects some of these newer compounds could be candidates to enter clinical studies in 2017 and 2018.”

Chronic HBV infects an estimated 240 million people worldwide, yet fewer than 10% of patients are cured by current therapies. Assembly scientists are aiming to achieve higher cure rates by targeting the HBV core protein, an essential viral protein involved in multiple critical functions throughout the HBV lifecycle. CpAMs allosterically inhibit core protein, meaning they can bind to it in a variety of ways that can result in different effects.  The findings in this presentation indicate that core protein is essential to establishment of cccDNA, a type of viral DNA that is associated with viral persistence in chronic HBV. Current HBV therapies do not target core protein, nor can they reduce nor silence cccDNA.

Presentation Poster 104, Preclinical Characterization of Potent Core Protein Allosteric Modifiers for the Treatment of Chronic Hepatitis B , will be presented on April 15, 2016 in the poster session on Viral Hepatitis: Hepatitis B & D in Exhibit Hall 8.1 from 8:00 am until 6:00 pm. The presentation will be posted under Events at the Investor section of Assembly’s website starting on April 15, 2016.

About Assembly Biosciences Assembly Biosciences, Inc. is a public biotechnology company advancing a novel class of oral biologic therapeutics designed to treat diseases of the gut microbiome and an innovative discovery platform of best-in-class oral small molecule therapeutics for the treatment of hepatitis B virus (HBV) infection. The company's Microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICEL TM , which allows for targeted oral delivery of live biologic and conventional therapies to the lower GI tract. The lead program from this platform, ABl-M101, is in development for the treatment of  C. difficile  infection. Assembly's HBV team has significant experience in infectious disease drug discovery and development and has collectively helped bring more than 10 anti-infective products to the market. The company's HBV-Cure Program is aimed at increasing the current low cure rate for patients with chronic HBV. It is pursuing a number of drug candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. For more information, visit  assemblybio.com .

Cautionary Statement Regarding Forward-Looking Statements The information provided herein contains estimates and other forward-looking statements regarding future events, including statements about the therapeutic potential of our HBV-Cure and Microbiome programs and the potential initiation of Phase 1 clinical studies of a CpAM. Such statements, which we intend to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: preclinical models may not be representative of disease behavior in clinical studies; our ability to retain necessary employees and to staff our operations appropriately; the components, timing, cost and results of clinical trials and other development activities involving our product candidates; the unpredictability of the preclinical and clinical development of our product candidates and of the duration and results of regulatory review of those candidates by the FDA and foreign regulatory authorities and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed with the Securities and Exchange Commission. It is not possible for Assembly management to predict all risks nor can Assembly assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Assembly may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Corporate: Assembly Biosciences, Inc. David Barrett dbarrett@assemblybio.com

Media: BLL Partners LLC Barbara Lindheim 212-584-2276 blindheim@bllbiopartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 43

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 85

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 19

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 294

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 164

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Cryptocurrency Through Sustainable Mining Solutions

Updated Category News Views 132

Ripple and Dogecoin Capture Market Attention Recently, Ripple, known by its trading symbol XRP, regained significant visibility in the cryptocurrency market following a major legal victory against a regulatory body. This resurgence has reignited interest among investors and enthusiasts alike. Meanwhile, Dogecoin has been experiencing a renaissance, driven by the ambitious...

Continue Reading
General Dynamics Sees Growth in Q2 Earnings and Revenue

Updated Category News Views 147

General Dynamics Q2 Financial Highlights General Dynamics reported remarkable financial results for the second quarter of 2025, showcasing a revenue of $13 billion, which marks an 8.9% increase compared to the same quarter last year. The company achieved operating earnings of $1.3 billion, translating to a diluted earnings per share (EPS) of $3.74, reflecting a 14.7%...

Continue Reading
FIU Shines as a Top Public University in New Ranking

Updated Category News Views 77

FIU Ranks High in TIME's New College List Alright, listen up. The latest college buzz isn't just noise—Florida International University (FIU) is sitting pretty at No. 23 among public universities in TIME's first crack at America's Best Colleges for the 2026-2027 term. They're also punching in at No. 62 overall out of 500 schools. For a university that's been...

Continue Reading
Recent Net Asset Value Disclosure for Hargreave Hale AIM VCT

Updated Category News Views 174

Understanding the Latest Net Asset Value Announcement The Hargreave Hale AIM VCT PLC has recently made an important announcement regarding its Net Asset Value (NAV). This provides valuable insights for investors and stakeholders looking to evaluate the fund's performance. It is crucial for those following this investment vehicle to stay informed about NAV updates, as...

Continue Reading
Orvana Minerals Corp. Reports Financial Results for Q1 FY2026

Updated Category News Views 191

Orvana Minerals Corp. Financial Performance Overview TSX:ORV Orvana Minerals Corp. (TSX: ORV) has recently disclosed its financial statements for the first quarter of the fiscal year 2026 through its subsidiary, Empresa Minera Paitití, S.A. (EMIPA). These unaudited results are now available for viewing on the Bolivian stock market. The disclosure marks an important...

Continue Reading